WfG is an AI–empowered platform that analyzes and classifies variants detected by NGS in tumor DNA, enabling oncologists to make informed treatment decisions based on biomarkers individual to their patient.Established scientific curation / analysis group Designed with technical development team clinical databaseDrove business goal achievement by serving as point of contact for remote internal and external teams across time zonesDirected client-facing contact Enhanced products through AI-based tool development and clinical trial matchingDeveloped framework for complex resistance mutations, detection of signature mutations

Personalized medicine company with focus on oncology. • Established and led curation / analytical group • Created and maintained the company’s medical information database  Developed physician education material and wrote summaries of genomic profiles  Designed cancer-type specific test panels Point of contact for private practice oncologists

Cancer Biology and Pharmacology:• Performed in vivo testing of drug candidates, from initial screening to IND filing• Characterization and evaluation of antibodies for cancer therapy in vitro and in vivo • In-depth characterization of >50 xenograft models for target validation (take rate, growth, invasion, angiogenesis, histology)• Lead multidisciplinary programs aimed at identifying and functionally validating novel targets for cancer therapy involving oncogenomics, in vitro cell-based assays, in vivo models• IACUC liaison: responsible for the writing of animal protocols, compliance of personnel with GLP and SOPs Target ID & validation: - Direct report to leading global pharmaceutical in partnership to validate and develop new cancer therapeutics- Design, development, and implementation of cell-based and in vivo assays - Nomination of new drug targets for collaboration with pharmaceutical industry partners- Designed studies and reported data to joint research teams- Wrote research grants to obtain financial support for Institute

Adjuct appointment in the department of cell biology, anatomy and neurobiology• Established research program in cancer biology• Lead program to evaluate FTY-720 for treatment of Ph+ leukemias in vivo• Member of the Institutional FACSCore committee (Cell sorting and Flow Cytometry): Advise and support of academic groups with design and implementation of protocols to isolate and characterize target cell population • Member of IRB committee

• Generation and characterization of inducible transgenic mouse models of leukemia• Development of in vivo models for targeting of hematopoietic and mesenchymal stem cells and progenitor cells • Established research program to study the role of the transcription factor C/EBPα in lung cancer• Supervision and guidance of postdoctoral fellows in animal care and procedures; supervision and coordination of daily activities of research technicians in animal husbandry and related molecular biology assays; responsible for introduction of medical research fellows to molecular and cell biology;